Histone Deacetylase Inhibitors through Click Chemistry
- 14 November 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (23) , 7417-7427
- https://doi.org/10.1021/jm8005355
Abstract
Histone deacetylase inhibitors (HDACi) are a relatively new class of chemotherapy agents. Herein, we report a click-chemistry based approach to the synthesis of HDACi. Fourteen agents were synthesized from the combination of two alkyne and seven azido precursors. The inhibition of HDAC1 and HDAC8 was then determined by in vitro enzymatic assays, after which the cytotoxicity was evaluated in the NCI human cancer cell line screen. A lead compound 5g (NSC746457) was discovered that inhibited HDAC1 at an IC50 value of 104 ± 30 nM and proved quite potent in the cancer cell line screen with GI50 values ranging from 3.92 μM to 10 nM. Thus, this click HDACi design has provided a new chemical scaffold that has not only revealed a lead compound, but one which is easily amendable to further structural modifications given the modular nature of this approach.Keywords
This publication has 52 references indexed in Scilit:
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and menNature Reviews Molecular Cell Biology, 2008
- A Metabolic Screening Study of Trichostatin A (TSA) and TSA-Like Histone Deacetylase Inhibitors in Rat and Human Primary Hepatocyte CulturesThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysisBreast Cancer Research and Treatment, 2005
- Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerThe Prostate, 2004